News | April 27, 2016

Mitralign System Earns CE Mark Approval for Functional Mitral Regurgitation

Patients treated with percutaneous annuloplasty system showed statistically significant improvement at 30 days and six months

Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval

April 27, 2016 — Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its notified body, the British Standards Institution (BSI), for the treatment of functional mitral regurgitation (FMR). This confirmation offers a unique new treatment alternative for patients with symptomatic functional mitral valve regurgitation. CE mark approval allows the company to market the Mitralign System in the European Union.

“The data show treatment with the Mitralign System is safe in FMR patients,” said Prof. Georg Nickenig of the University of Bonn. “Due to its versatility and small footprint, the device can be considered a front-line treatment option for patients with mitral regurgitation.”

Data from the CE mark study demonstrated the Mitralign System met both its 30-day safety and its six-month performance endpoints. In the prospective, multi-center, single arm study, patients treated with the Mitralign System demonstrated statistically significant (p<0.05) improvements in 6-minute walk test, left ventricular dimensions and remodeling, reversing the course of heart dilation due to heart failure.

Mitralign is the only company to provide a direct transcatheter annuloplasty system designed to treat both FMR and tricuspid regurgitation (TR). Both the Mitralign and Trialign Systems feature a customizable therapy solution in concert with an extremely small footprint that leaves all clinical options open for the physician.

MPAS is not available for sale in the United States. The Trialign System is currently enrolling patients in an early feasibility investigational device exemption (IDE) study in the U.S. and is not approved for sale or distribution.

For more information: www.mitralign.com


Related Content

News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
Subscribe Now